Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065

BIOCORP

(ALCOR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biocorp : Wins the Frost & Sullivan Product Line Strategy Leadership Award

share with twitter share with LinkedIn share with facebook
share via e-mail
05/09/2016 | 12:01pm EDT

BIOCORP stood out in the field of digital health solutions and smart drug delivery systems throughout Europe in 2015.

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of innovative medical and drug delivery devices, announced today that it has won the European Product Line Strategy Leadership award granted by prestigious consulting firm Frost & Sullivan.

This product leadership award recognizes European companies that have demonstrated an outstanding ability to develop innovative products in a given field. Analysts and consultants from Frost & Sullivan chose the award winner after carrying out a study to identify the best strategies in Europe — particularly for enhancing the customer experience.

BIOCORP stood out from other companies on several complementary criteria highlighting its innovations in the development of medical devices for the pharmaceutical industry and consolidating its position as a pioneer in the field of connected devices: Breadth, Scalability, Technology Leverage, Features, Supply Chain Reliability, Price/Performance Value and Brand Equity.

Click here to consult the Best Practice Research: http://bit.ly/1rydpRI

Frost & Sullivan underlines the high potential of various technologies developed by BIOCORP, which has addressed several global healthcare delivery concerns, finding markets enthusiastically waiting for its solutions. BIOCORP has accurately amalgamated novel and emerging technologies to dramatically increase the access to new product developments by combining the latest innovations in digital transformation with advanced therapeutics’ delivery and administration systems. BIOCORP has made the difference by providing a more automated, less-invasive, more personalized, and precise therapeutics administration technology, along with more comfortable and easier-to-use devices for both patients and clinicians1.

“We are honored to receive this award from Frost & Sullivan. It is highlighting the potential of our innovating technology, which represents a genuine competitive asset and enables us to come up with unique and high-value solutions for the pharmaceutical industry, as well as our strong growth potential on a market eager for new solutions. It is a fair acknowledgment of our team members’ hard work”, said Jacques Gardette, BIOCORP’s CEO.

ABOUT FROST & SULLIVAN
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

ABOUT BIOCORP
Founded in 2004 in Issoire (near Clermont-Ferrand), France, Biocorp is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, Biocorp is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, Biocorp continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 43 employees.
Biocorp is listed on Alternext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit: www.biocorp.fr
Follow us on Twitter @BIOCORPSystems

1 Frost & Sulllivan : Product Line Strategy Leadership Award, Digital Health Solutions and Smart Drug Delivery Systems – Europe http://bit.ly/1rydpRI


© Business Wire 2016
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOCORP
06/30BIOCORP : Signs Distribution Agreement for Mallya Technology With Roche Diabetes..
BU
06/22BIOCORP : Announces Initiation of Coverage by Gilbert Dupont
BU
06/19BIOCORP : and Théa Sign a Partnership for the Development of Innovative Digital ..
BU
04/09BIOCORP : 2019 annual results
PU
04/09BIOCORP : 2019 Annual Results
BU
04/09BIOCORP : Annual results
CO
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
PU
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
BU
02/12BIOCORP : Strong Revenue Growth In 2019
BU
More news
Financials
Sales 2020 15,3 M 17,4 M 17,4 M
Net income 2020 0,60 M 0,68 M 0,68 M
Net cash 2020 1,17 M 1,33 M 1,33 M
P/E ratio 2020 183x
Yield 2020 0,05%
Capitalization 116 M 132 M 132 M
EV / Sales 2019
EV / Sales 2020 7,53x
Nbr of Employees 52
Free-Float 51,3%
Chart BIOCORP
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 31,35 €
Last Close Price 27,40 €
Spread / Highest target 16,8%
Spread / Average Target 14,4%
Spread / Lowest Target 12,0%
EPS Revisions
Managers
NameTitle
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCORP112.40%129
JOHNSON & JOHNSON1.41%389 709
ROCHE HOLDING AG5.59%300 114
MERCK & CO., INC.-13.96%197 511
PFIZER, INC.-10.08%195 697
NOVARTIS AG-11.32%191 193